Literature DB >> 7249499

Systemic and cardiac hemodynamic interactions between clonidine and minoxidil.

M Velasco, P Andrews-Figueroa, A Ramiŕez, J Morillo, A Urbina-Quintana, R Aliendres, O Hernańdez-Pieretti.   

Abstract

We examined the hemodynamic interaction between clonidine, a centrally acting antiadrenergic drug, and minoxidil, a potent antihypertensive vasodilator in 10 inpatients with refractory or accelerated hypertension or both. Clonidine in oral doses of 150 to 900 micrograms/day decreased average mean blood pressure 18.6 mm Hg (p less than 0.01), average heart rate 16.4 bpm (p less than 0.01), limb blood flow 1.63 ml/100 gm . min (p less than 0.05), and plasma renin activity 1.13 ng/ml . hr (p less than 0.025). It also increased the pre-ejection period index 12.4 msec (p less than 0.001), but did not alter the cardiac or total peripheral resistance indices. The addition of minoxidil in oral doses of 5 to 22.5 mg/day further decreased average mean blood pressure 24.2 mm Hg (p less than 0.01), preejection period index 20.6 msec (p less than 0.01), limb vascular resistance 13.2 mm Hg/min . 100 gm/ml (p less than 0.05), and total peripheral resistance 13.3 mm Hg/min . m2/l (p less than 0.01), pre-ejection period index 20.6 msec (p less than 0.01), limb vascular resistance 13.2 mm Hg/min . 100 gm/ml (p less than 0.05), and total peripheral resistance 13.3 mm Hg/min . m2/l concluded that clonidine can be used as an alternative to beta-adrenergic blockers to counteract the increased sympathetic nervous activity minoxidil induces.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7249499     DOI: 10.1038/clpt.1981.142

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

Review 1.  Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

Authors:  Hamish Cg Prosser; Cynthia Gregory; Dagmara Hering; Graham S Hillis; Greg Perry; Johan Rosman; Carl Schultz; Mark Thomas; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

2.  Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients.

Authors:  M Velasco; A Urbina-Quintana; J Morillo; H Vizcarrondo; A Ramirez; E Hernández; O Hernández-Pieretti
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.